Filing Details

Accession Number:
0000899243-15-007138
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-10-26 19:03:51
Reporting Period:
2015-10-22
Filing Date:
2015-10-26
Accepted Time:
2015-10-26 19:03:51
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875045 Biogen Inc. BIIB Biological Products, (No Disgnostic Substances) (2836) 330112644
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1361754 J Alexander Denner Biogen Inc.
225 Binney Street
Cambridge MA 02142
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-10-22 210,000 $277.80 210,000 No 4 P Indirect See Footnotes
Common Stock Acquisiton 2015-10-23 100,000 $276.77 310,000 No 4 P Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnotes
No 4 P Indirect See Footnotes
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 7,890 Direct
Footnotes
  1. On October 22, 2015, each of Sarissa Capital Domestic Fund LP, a Delaware limited partnership ("Sarissa Domestic") and Sarissa Capital Offshore Master Fund LP, a Cayman Islands exempted limited partnership ("Sarissa Offshore"), purchased an aggregate of 128,806 and 81,194 shares, respectively, of common stock of Biogen Inc.
  2. On October 23, 2015, each of Sarissa Domestic and Sarissa Offshore purchased an aggregate of 61,336 and 38,664 shares, respectively, of common stock of Biogen Inc.
  3. Sarissa Capital Management GP LLC, a Delaware limited liability company ("Sarissa Capital GP"), is the general partner of Sarissa Capital Management LP, a Delaware limited partnership ("Sarissa Capital"), the investment advisor to the Sarissa Funds. Alexander Denner is the Chief Investment Officer of Sarissa Capital and the managing member of Sarissa Capital GP. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that the Sarissa Funds directly beneficially own.
  4. Dr. Denner disclaims beneficial ownership of the shares being reported on this Form 4 except to the extent of his pecuniary interest therein.